Response and Survival Following Second-Line Therapy in 113 Patients with Steroid-Refractory Acute Graft-Versus-Host Disease  by Trottier, Bryan et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354 S351Results: 156 patients, median age 5 (range 0-22) years, were
included; 50 for a malignancy; 22 AML, 22 ALL, and 6 other.
127 (81%) patients received Bu-based and 29 (19%) TBI-based
conditioning. In multivariate analyses, above median num-
ber PIRCHE-I were associated with lower probability of
relapse (HR 0.139, p¼0.006, Fig 1), and a trend for improved
disease-free survival (HR 0.411, p¼0.086). This effect was not
present for PIRCHE-II. In the whole cohort, PIRCHE-I or eII
were neither associated with acute-GVHD grade II-IV (HR
0.747, p¼0.466, HR 1.263, p¼0.554) nor extensive chronic
GVHD (HR 1.502, p¼0.671, HR 3.420, p¼0.293), nor TRM (HR
1.753, p¼0.198, HR 0.991, p¼0.983, for PIRCHE-I and eII
respectively).
Conclusion: High numbers of PIRCHE-I lead to improved
GVL effects after UCBT, while GVHD was not impacted by the
number of PIRCHE. PIRCHE may provide an additional tool
for individualized donor selection to improve survival
chances. The effects observed in this study need to be vali-
dated in other cohorts.
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Introduction: Chronic graft-versus-host-disease (cGvHD) is
a late complication (>90 days) after allogeneic hematopoi-
etic stem cell transplantation (HSCT). Symptomsmight occur
inmultiple organs and vary frommild to severe. In this study,
the NIH criteria were used to group the patients. We per-
formed an extensive immune-phenotypic analysis using cells
and plasma from patients diagnosed with and without
cGvHD. The aim of the study is to gain information on
possible markers that could be used by clinicians to aid in the
diagnosis of cGvHD.
Methods: Peripheral blood samples were obtained from
patients  1 year post-HSCT with an acute GvHD no higher
than grade I. Patients were divided into 4 groups: no
(N¼10), mild (N¼6), moderate (N¼5) and severe cGvHD
(N¼8). Cytokine levels were measured by Luminex and an
immune-phenotypic analysis was done by multicolor ﬂow
cytometry. Univariate analysis comparing the different
patient groups was done with the Mann-Whitney
U test.
Results: Due to usage of immunosuppressive treatments in
the moderate and severe cGvHD groups, we chose to
compare patients with no versus mild cGvHD and moderateTable
Factors associated with day 28 CR/PR and 6-month NRM
Factor N OR of CR/PR (95% CI
Second Line Rx
ATG* 50 1.0
MMF 28 2.1 (0.7-6.8)
Boost 25 1.9 (0.5-7.6)
Other 10 0.2 (0.02-2.2)
GVHD Risk Score (at 2nd Rx)
Standard* 55 1.0
High 58 0.3 (0.1-0.9)
Time from Onset to 2nd Rx
214 days* 63 1.0
>14 50 0.3 (0.1-1.0)versus severe cGvHD. Expression of the cell activation
marker CD38 was higher on total T cells and CD8+ T cells
(p¼0.005 for both subsets) in mild cGvHD patients compared
to patients without cGVHD. Furthermore, severe cGvHD pa-
tients had higher levels of CD8+ Tcells (p¼0.03) than patients
with moderate cGvHD. Additionally, several Th2-associated
cytokines were down regulated in severe cGvHD patients,
compared to the other patient groups. An analysis was also
done based on the presence of cGvHD in speciﬁc organs
(lung, mouth and skin) within the moderate and severe
cGvHD group. In patients with lung cGvHD; both the
expression of degranulation marker CD107a (p¼0.003) on T
cells and the expression of KIR receptor CD158b on NK cells
negative for the Fc receptor CD16 (p¼0.035) were found to be
lower. Anti-inﬂammatory cytokine IL-10 was decreased
(p¼0.018) in patients with mouth cGvHD. Lastly, CD158b+
CD16+ NK cells and total CD158b+ NK cells were found to be
less frequent in patients with skin cGvHD (p¼0.017 for both
subsets).
Discussion: Mild and severe cGvHD patients appear to
have a more activated and cytotoxic immune-phenotype
compared to patients with no and moderate cGvHD,
respectively. Additionally, patients with speciﬁc organ-
oriented cGvHD seem to have a lower percentage of NK
cell subsets. In conclusion, it appears that patients with an
increasing severity of cGvHD have a more activated
cytotoxic phenotype, which seems to mostly depend on
CD8+ T cells and not on NK cells. By studying the
phenotype of the immune system in these cGvHD pa-
tients, we can gain new insights in the pathogenesis
behind cGvHD. Our ﬁndings, i.e. distorted immune cell
phenotypes, could potentially be used as biomarkers in
the diagnostics of cGvHD.512
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Background: Steroid-refractory acute graft-versus-host
disease (SR-aGVHD) remains the major, non-relapse obstacle
to successful hematopoietic cell transplantation (HCT).
Evolving donor and cell sources, conditioning regimens and
GVHD prophylaxis are altering the ﬁeld of HCT. We evaluated) P RR of NRM (95% CI) P
1.0
0.20 0.5 (0.2-1.1) 0.07
0.36 0.2 (0.1-0.6) <0.01
0.19 0.4 (0.1-1.1) 0.08
1.0
0.04 1.0 (0.5-1.7) 0.89
1.0
0.05 1.2 (0.6-2.6) 0.57
Figure 1. Six-month NRM is lower among steroid boost recipients compared
to ATG
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in this modern era.
Methods: We retrospectively analyzed day 28 response
rates and clinical outcomes of 113 HCT patients (median
age 39 years, range 1-75) who received second-line
therapy for SR-aGVHD from 1998-2012 at the University of
Minnesota.
Results: Patients received grafts from 43 related (38
matched, 5 mismatched), 31 unrelated (23 HLA 6-8/8, 8
HLA 25/8) and 39 cord blood donors (23 HLA 6-8/8, 16 HLA
25/8); 76 patients (67.3%) received myeloablative regi-
mens. Second-line therapy consisted of ATG (44.2%), MMF
(24.8%), steroid boost (22.1%) or other (8.8%). Patients
receiving ATG had higher-risk GVHD Risk Scores (Mac-
Millan et al, Br J Haem, 2012) at second-line initiation
compared with patients receiving MMF or steroids. At day
28, overall response (complete response [CR]/partial
response [PR]) was observed in 32 patients (28%). All
therapies had similar responses. In multivariate analysis,
factors associated with day 28 CR/PR included GVHD Risk
Score and days from onset of aGVHD to second-line
therapy (Table); Six-month non-relapse mortality (NRM)
was lower among patients receiving steroid boosts (24%
[7-41%, 95% CI]) vs. ATG (64% [48-90%, 95% CI]) with no
differences vs. MMF or other therapies (P¼0.01, Figure 1).Figure 2. Six-month OS is increased among day 28 second-line
responders.In multivariate analysis, use of steroids vs. ATG was
associated with reduced 6-month NRM (Table). Overall
survival (OS) at 6 months was increased among day 28
responders (68% [48-81, 95% CI]) vs. non-responders (NR)
(45% [33-57, 95% CI]) (P¼0.03, Figure 2). Donor and cell
source, conditioning regimen and age did not impact
response, NRM or OS.
Conclusions: Effective therapy for SR-aGHVD remains
inadequate. Day 28 CR/PR was similar among second-line
therapies. ATG recipients experienced higher rates of
NRM but also exhibited higher-risk GVHD by Risk Score.
Identiﬁcation of high-risk GVHD at initial onset using the
GVHD Risk Score may identify patients likely to fail
upfront steroids in need of additional or alternative
agents.513
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Background: A primary goal in the management of chronic
graft-versus-host disease (cGVHD) is to prevent the pro-
gression of organ-speciﬁc and global functional impairment
due to the natural history of cGVHD or its treatment. We
tested a deﬁnition of progressive impairment in a multi-
center cohort.
Methods: Of the measures recommended by the 2005 NIH
Consensus Conference, changes in 21 items having face val-
idity for “impairment” were selected from these categories:
clinician-reported organ involvement; FEV1; and patient-
reported performance status and physical function.
Results: 575 patients were evaluated, and 237 (41%) met
criteria for progressive impairment during a median of 39.9
(range 3.8 to 69.2) months of follow-up. 125 (53%) had pro-
gressive impairment on the basis of clinically assessed mea-
sures, 61 (26%) on the basis of patient-reported performance
status or physical function, and 51 (22%) on the basis of more
than one category. The top 5 items indicating progressive
impairment were: decline in FEV1 by 10% (81/237), decrease
in the Human Activity Proﬁle Adjusted Activity Score (HAP
AAS) score by 0.5 standard deviation (76/237), increase in
the global measure of skin sclerotic changes (70/237), increase
in the fascia score (57/237), and increase in the global skin
score (51/237). Rates of survival without progressive impair-
ment or relapse were 72% at 6 months, 52% at 12 months, and
35% at 24 months. Cumulative incidences of progressive
impairmentwere 20% at 6months, 33% at 12months, and 43%
at 24 months. Patients with progressive impairment had sig-
niﬁcant worsening in clinician and patient-assessed cGVHD
severity, symptoms and quality of life as compared to those
without progressive impairment (Table).
Conclusion: Treatments that prevent unacceptable clinical
deterioration in patients with chronic GVHD could be iden-
tiﬁed by using survival without progressive impairment as
an endpoint in clinical trials.
